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Abstract – Porcine reproductive and respiratory syndrome virus (PRRSV) can induce reproductive
disorders and is involved in the porcine respiratory disease complex, causing tremendous economic losses
to the swine industry. Inactivated PRRSV vaccines are preferred over attenuated vaccines because of their
safety and ﬂexibility towards emerging virus strains, but the efﬁcacy of current inactivated PRRSV vaccines
is questionable. In this study, experimental inactivated PRRSV vaccines were developed, based on two
formerly optimized inactivation procedures: UV irradiation and treatment with binary ethylenimine (BEI).
In a ﬁrst experiment, it was shown that vaccination with UV- or BEI-inactivated virus in combination with
Incomplete Freund’s Adjuvant induced virus-speciﬁc antibodies and strongly primed the virus-neutralizing
(VN) antibody response. Subsequently, the inﬂuence of adjuvants on the immunogenicity of neutralizing
epitopes on the inactivated virus was investigated. It was shown that vaccination with BEI-inactivated virus
in combination with a commercial oil-in-water adjuvant induced high titers (3.4 log2) of VN antibodies in
6/6 pigs, instead of only priming the neutralizing antibody response. After challenge, neutralizing antibody
titers in these vaccinated animals rose to a mean value of 5.5 log2, and the duration of the viremia was
reduced to an average of 1 week. This study shows that, by the use of an optimized inactivation procedure
and a suitable adjuvant, inactivated PRRSV vaccines can be developed that induce VN antibodies and offer
partial protection upon challenge.
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1. INTRODUCTION
Porcine reproductive and respiratory syn-
drome virus (PRRSV) is an enveloped posi-
tive-stranded RNA virus that belongs to the
family of the Arteriviridae in the order of the
Nidovirales [9, 25]. PRRSV can cause severe
reproductive failure in sows, characterized by
late term abortion, early farrowing, stillbirth
and the birth of weak piglets, and is associated
with the porcine respiratory disease complex in
combination with secondary infections [3, 4,
26–28, 30]. The virus is present in a majority
of swine producing countries around the world
and gives rise to enormous economic losses in
the swine industry [17]. Virus-neutralizing
(VN) antibodies against PRRSV protect against
viremia, virus replication in lungs, transplacental
spreading of the virus and reproductive failure
[12–14, 20]. However, VN antibodies only
appear in low amounts around 4 weeks or more
after PRRSV infection, which is in contrast with
the fast appearance of high amounts of non-
neutralizing antibodies [7, 34]. Attenuated as* Corresponding author: hans.nauwynck@ugent.be
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well as inactivated PRRSV vaccines are fre-
quently used in the ﬁeld. Attenuated vaccines
induce VN antibodies and protect against vire-
mia, virus replication in lungs and virus-
induced respiratory and reproductive disorders
[10, 23, 35]. However, the protective immune
response induced by attenuated PRRSV vac-
cines is inﬂuenced by genetic diversity, as these
vaccines do not always sufﬁciently protect
against virus strains that are genetically differ-
ent from the vaccine virus strain [11, 15].
Besides, there are major concerns about the
safety of attenuated PRRSV vaccines, as the
vaccine virus on itself can cause viremia and
can spread transplacentally and horizontally
with the risk of reverting to virulence [2, 18,
22]. Inactivated vaccines on the other hand
are safe and it has been shown by Misinzo et al.
that it is possible to stimulate the VN antibody
response in naı¨ve piglets by immunization with
inactivated PRRSV [16]. Commercially avail-
able inactivated PRRSV vaccines however do
not induce VN antibodies and do not sufﬁ-
ciently protect against viremia [19, 24, 35].
VN antibodies inhibit replication of PRRSV
in porcine alveolar macrophages (PAM), the
in vivo host cell type for the virus, by blocking
attachment to and internalization in the cell [5].
Hence, domains on the virus particle that are
involved in binding and internalization are
involved in virus neutralization. Delrue et al.
[6] recently showed that certain inactivation
procedures do not conserve viral entry-associ-
ated domains on the virus particle, while others
fully do. These ﬁndings suggest that the latter
inactivation procedures are preferable for the
development of inactivated PRRSV vaccines
that aim to induce VN antibodies. In the present
study, two inactivation procedures that conserve
viral entry-associated domains, namely treat-
ment with ultraviolet (UV) radiation and treat-
ment with binary ethylenimine (BEI), were
used in the development of experimental inacti-
vated PRRSV vaccines. The ability of such
vaccines to induce a VN antibody response
and protect against viremia after challenge
was determined. A commercial inactivated
PRRSV vaccine was simultaneously tested
to have a reference vaccine available in the
used experimental design. Subsequently, the
inﬂuence of different adjuvants on the immuno-
genicity of the inactivated virus was deter-
mined. After all, an experimental inactivated
PRRSV vaccine was developed that induced
VN antibodies and reduced the duration of vire-
mia after infection.
2. MATERIALS AND METHODS
2.1. Virus production and puriﬁcation
The PRRSV Lelystad virus (LV) strain, propa-
gated in Marc-145 cells, was used for vaccine prep-
aration [30]. The ﬁfth passage cell culture
supernatant was ﬁltrated through a 0.45 lm ﬁlter
and virus was concentrated from the supernatant by
ultracentrifugation at 112 000 g for 2 h using a Type
35 rotor (Beckman Coulter, Analis, Ghent, Belgium).
Subsequently, virus was semi-puriﬁed by ultracentri-
fugation at 100 000 g for 3 h through a 30% sucrose
cushion, using a SW41Ti rotor (Beckman Coulter),
resuspended in phosphate buffered saline and stored
at 70 C. Challenge virus consisted of the ﬁfth
passage of PRRSV LV, propagated in PAM that were
derived from gnotobiotic piglets.
2.2. Virus inactivation
Before inactivation, puriﬁed virus was diluted in
RPMI 1640 to a titer of 108 TCID50/mL. Inactivation
of PRRSV with BEI was performed as described by
Bahnemann [1]. A 0.1 M stock of BEI was prepared
by cyclization of 2-bromoethylamine in 0.175 M
NaOH for 1 h at 37 C and stored at 4 C. Virus
was inactivated by incubation with 1 mMBEI during
24 h at 37 C. Afterwards, BEI was neutralized by
incubation with 0.1 mM Na-thiosulphate for 2 h at
37 C. Inactivation of PRRSV with UV radiation
was performed by irradiation of the virus suspension
with 1 000 mJ/cm2, using a UV crosslinker (UVP,
Inc., BRS, Drogenbos, Belgium). Inactivated virus
was stored at 70 C.
2.3. Analysis of complete inactivation
To verify if virus was completely inactivated,
1 mL of each inactivated virus suspension was inoc-
ulated on Marc-145 cells in a 150 cm2 tissue culture
ﬂask with 50 mL of medium. The cells were culti-
vated for 1 week at 37 C, followed by transfer of
the supernatant to a fresh culture and incubation for
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another week. Inoculation of Marc-145 cells with
1 mL of non-inactivated virus was included as posi-
tive control. Cells were analyzed for cytopathic effect
(CPE) and all cell cultures were ﬁxed with 100%
methanol at 20 C, followed by an immunoperox-
idase staining with monoclonal antibody P3/27
against the PRRSV nucleocapsid protein to detect
infected cells [31].
2.4. Analysis of virus internalization
in macrophages
Virus internalization of live and inactivated virus
in PAM was performed as described by Delputte
et al. [5]. PAM were inoculated with the virus sus-
pensions and incubated for 1 h at 37 C with 5%
CO2. Cells were washed to remove unbound virus
particles, ﬁxed with 100% methanol at 20 C,
and virus particles were stained with mouse monoclo-
nal antibody P3/27 against the PRRSV nucleocapsid
protein and FITC-labelled goat anti-mouse antibody.
The amount of internalized virus particles in PAM
was determined with a Leica TCS SP2 laser-scanning
spectral confocal system (Leica Microsystems, Groot
Bijgaarden, Belgium) in ﬁve randomly selected cells
for each condition. The mean number of internalized
virus particles for non-inactivated virus was equalized
to 100% and the relative % of internalization for inac-
tivated virus was determined.
2.5. Experimental design of animal studies
All piglets were derived from a PRRS-negative
farm and their PRRSV-negative status was conﬁrmed
by immunoperoxidase monolayer assay (IPMA).
2.5.1. Vaccination with a commercial inactivated
vaccine and UV- or BEI-inactivated virus
in Incomplete Freund’s Adjuvant
In a ﬁrst experiment, 24 piglets were randomly
assigned to four treatment groups. A ﬁrst group
(group A) served as mock-vaccinated control group
and received 1 mL RPMI in 1 mL Incomplete
Freund’s Adjuvant (IFA, Sigma-Aldrich, Bornem,
Belgium) at 6 and 10 weeks of age. The other three
groups were vaccinated twice intramuscularly at
6 (primo vaccination) and 10 (booster vaccination)
weeks of age. Group B was vaccinated with 2 mL
of a commercial European-type inactivated PRRSV
vaccine (Progressis, Merial, Brussels, Belgium).
Group C received 1 mL of UV-inactivated virus
in 1 mL IFA and group D received 1 mL of
BEI-inactivated virus in 1 mL IFA. Four weeks after
the booster vaccination, all pigs were challenged by
intranasal inoculation of 106 TCID50 LV. Blood
was taken weekly after vaccination and at 0, 3, 5,
7, 10, 14, 21, 28 and 35 days post challenge. Serum
was collected and stored at 70 C. Serum samples
for IPMA and VN antibody detection were incubated
during 30 min at 56 C prior to freezing.
2.5.2. Vaccination with BEI-inactivated virus
in Incomplete Freund’s Adjuvant
or Alhydrogel
In a second experiment, 18 piglets were ran-
domly assigned to three treatment groups. Group
E served as mock-vaccinated control group and
received 2 mL RPMI. The other two groups were
vaccinated twice with 1 mL BEI-inactivated virus
in 1 mL adjuvant. For group F, IFA was used as
adjuvant, while for group G, the inactivated virus
was diluted in a 16% aluminium hydroxide colloidal
gel (Alhydrogel, Sigma-Aldrich). The same experi-
mental design was used as for the ﬁrst experiment,
but blood was only sampled up till 21 days post
challenge.
2.5.3. Vaccination with BEI-inactivated virus
in Alhydrogel or Suvaxyn o/w adjuvant
In a third experiment, 18 piglets were randomly
assigned to three treatment groups. Group H served
as mock-vaccinated control group and received
2 mL RPMI at the time of vaccination. The other
two groups were vaccinated twice with 1 mL BEI-
inactivated virus in 1 mL adjuvant. For group I,
Alhydrogel was used as adjuvant, while for group
J, an oil-in-water (o/w) diluent that is used in the
commercial pseudorabies virus vaccine Suvaxyn
Aujeszky (Fort Dodge Animal Health, Kelmis,
Belgium) was used. The same experimental design
was used as for the former experiments, and blood
was sampled up till 32 days post challenge.
2.6. Antibody detection and virus titration
PRRSV-speciﬁc serum antibody titers were deter-
mined by IPMA as described by Labarque et al. [12].
VN antibody titers were detected by a seroneutraliza-
tion (SN) test on Marc-145 cells. Brieﬂy, a 1/2 dilu-
tion series of serum was prepared and an equal
volume of virus with a titer of 2 · 103 TCID50/mL
was added to each dilution and incubated for 1 h at
37 C. Subsequently, the serum-virus mixture was
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transferred to a 96-well plate containing conﬂuent
Marc-145 cells, and the cells were analyzed for
CPE at 7 days post inoculation. The VN antibody
titer was deﬁned as the reciprocal of the highest dilu-
tion that inhibited CPE in 50% of the inoculated
wells. Virus titers in serum were determined by virus
titration on PAM, followed by immunoperoxidase
staining with monoclonal antibody P3/27 against
the nucleocapsid protein of PRRSV [12].
2.7. Statistical analysis
Internalization in macrophages was analyzed by
one-way analysis of variance and p < 0.05 was taken
as the level of statistical signiﬁcance. Antibody and
virus titers were analyzed by Kruskall–Wallis test,
followed by Dunn’s multiple comparisons test to
determine differences between groups at different
time points. An overall p value of 0.05 was used
for this mutiple comparisons test. All statistical anal-
yses were performed using GraphPad Prism version
5.0a (GraphPad Software, San Diego, California,
USA).
3. RESULTS
3.1. Virus inactivation and control
of internalization
For each vaccination experiment, a PRRSV
virus suspension with a titer of 108 TCID50/
mL was inactivated with either UV radiation
or BEI. Complete inactivation was evaluated
by passage of a sample on Marc-145 cells, fol-
lowed by immunostaining for the nucleocapsid
protein of PRRSV to detect infected cells. Cells
that were inoculated with inactivated virus
never showed any CPE or positive nucleocap-
sid staining, while a clear CPE as well as nucle-
ocapsid staining was observed on cell cultures
that were inoculated with non-inactivated virus.
To determine whether inactivation had inﬂu-
enced the capacity of the virus to get internal-
ized in PAM, an internalization experiment
was performed with BEI- or UV-inactivated
virus and a non-inactivated virus suspension
as positive control. The relative percentage of
internalized virus particles per cell did not differ
signiﬁcantly (p = 0.08) between UV-inactivated
(86 ± 11), BEI-inactivated (131 ± 15) and not
inactivated virus (100 ± 13).
3.2. Vaccination with a commercial inactivated
vaccine and UV- or BEI-inactivated virus
in Incomplete Freund’s Adjuvant
3.2.1. Virus-speciﬁc and -neutralizing antibodies
PRRSV-speciﬁc antibodies were not
detected by IPMA in any of the pigs of the
adjuvant control group (group A) before chal-
lenge (Fig. 1, upper panel). Of pigs that were
vaccinated with the commercial inactivated vac-
cine (group B), one pig transiently showed a
positive IPMA antibody titer after vaccination
and another had seroconverted at the day of
challenge, while the other pigs remained sero-
negative up till the time of challenge. In con-
trast, all pigs that were vaccinated with the
experimental UV-inactivated (group C) or
BEI-inactivated (group D) vaccine already
showed positive antibody titers at 3 weeks after
the primo vaccination. After the booster vacci-
nation antibody titers rose to values as high as
normally seen after PRRSV infection in naı¨ve
pigs [12]. After challenge, all pigs had serocon-
verted at day 10. Antibody titers in group B
were slightly higher than in group A, however
differences were not signiﬁcant. In group C as
well as group D, antibody titers were signiﬁ-
cantly higher compared to group A starting
from 1 week after booster vaccination up till
1 week post challenge.
Before challenge, none of the pigs showed
VNantibodies, except for onepig of groupD that
showed an SN antibody titer of 1.0 log2 at 2
weeks after the booster vaccination and at the
day of challenge (Fig. 1, lower panel). After chal-
lenge, one pig of group A showed a transient SN
antibody titer at day 10, however for all other
adjuvant control pigs, VN antibodies only
appeared between 3 and 5 weeks post challenge
and one pig even remained negative during the
entire experiment. Only four pigs of group B
showedVN antibodies after challenge, two start-
ing from 10 days, one at 4weeks and another at 5
weeks post challenge, andVN antibody titers did
not differ between group A and B at any time
point. In contrast, all pigs of group C and D
showed VN antibodies after challenge. In group
C, ﬁve animals seroconverted for VN antibodies
within the ﬁrst 2 weeks after challenge, and the
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Figure 1. PRRSV-speciﬁc IPMA antibody titers (log2) (upper panel) and VN antibody titers (log2) (lower
panel) after vaccination and challenge for group A (Mock-vaccinated control), B (Progressis), C (UV-
inactivated virus) and D (BEI-inactivated virus). = primo vaccination, = booster vaccination and
= challenge. Symbols represent individual animals and lines represent mean IPMA or SN titers for each
group. The dashed line gives the mean titers for group A. The dotted line gives the detection limit for the
IPMA or SN test.
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sixth one after 5 weeks. VN antibody titers were
signiﬁcantly higher in group C compared to
group A at 2 weeks post challenge, reaching
mean values of 2.9 log2. In group D, one pig
already had VN antibodies before challenge
and starting from 1 week post challenge all pigs
of this group showed a positiveSNantibody titer,
except for one animal that became positive 1
week later. VN antibody titers were signiﬁcantly
higher in groupD compared to group A at 10, 14
and 21 days post challenge, reaching mean val-
ues of 2.6, 2.5 and 2.0 log2 respectively.
3.2.2. Viremia
Virus was not detected in serum at 1 week
after each immunization and at the day of chal-
lenge, conﬁrming that all vaccines were properly
inactivated. After challenge, all animals showed
viremia. Figure 2 represents virus titers (log10
TCID50/mL) post challenge for each group. In
group A, a maximum mean virus titer of 3.5
log10TCID50/mLwas reached at day 5 post chal-
lenge and a second peak of 3.1 log10 TCID50/mL
was observed at day 10. Subsequently, a decline
in virus titers was observed, and virus could no
longer be detected at 2, 3 or 4 weeks after chal-
lenge (two animals per time point). Mean virus
titers in group Bwere slightly lower compared to
those in group A, being 3.1 log10 TCID50/mL
at 5 days and 2.0 log10 TCID50/mL at 10 days
post infection, but no signiﬁcant differences
could be detected at any time point between
groupAandgroupB. Inone animal of this group,
virus was cleared from the blood at 1 week post
challenge, in another one at 10 days and in the
other animals at 2, 3 or 4 weeks. The mean virus
titer for group C was 2.7 log10 TCID50/mL at 5
days and 2.5 log10 TCID50/mL at 10 days post
challenge, however titers were not signiﬁcantly
different from those in groupA at any time point.
Nevertheless, viremia in group C was already
cleared at 2 weeks post challenge for ﬁve ani-
mals, and at 3 weeks for the sixth one. Finally,
the mean virus titer for group D was 2.6 log10
TCID50/mL at 5 days post challenge and 1.4
log10 TCID50/mL at day 10, and at the latter time
point virus titers were signiﬁcantly reduced,
compared to group A. Viral clearance was
observed for one animal per time point at 7, 10,
14 and 21 days and for two animals at 28 days
post challenge.
3.3. Vaccination with BEI-inactivated virus
in Incomplete Freund’s Adjuvant
or Alhydrogel
3.3.1. Virus-speciﬁc and -neutralizing antibodies
All mock-vaccinated animals (group E)
showed virus-speciﬁc antibodies starting from
10 days post challenge (Fig. 3, upper panel).
Animals that were vaccinated with BEI-
inactivated virus in combination with IFA adju-
vant (group F) seroconverted at 2 or 3 weeks
after the ﬁrst vaccination. Two animals that
were vaccinated with BEI-inactivated virus in
combination with Alhydrogel as adjuvant
(group G) showed virus-speciﬁc antibodies
from 2 weeks after the ﬁrst vaccination, and
the other animals in this group starting from 2
weeks after booster vaccination. Antibody titers
in both vaccinated groups were signiﬁcantly
higher compared to the control group from 2
weeks after booster vaccination up till 10 days
post challenge, and antibody titers in group F
were generally higher compared to group G.
VN antibodies could not be detected in
group E at any time point, except for one ani-
mal at 2 weeks post challenge (Fig. 3, lower
panel). None of the vaccinated animals showed
VN antibodies before challenge, but VN anti-
bodies already appeared between 5 and 10 days
after challenge in group F, and between 7 and
10 days after challenge in group G. VN anti-
body titers were signiﬁcantly higher in both
vaccinated groups, compared to the control
group starting from 10 days post challenge up
till the end of the study. Mean VN antibody
titers were in general 1 log2 higher in group F
than in group G, reaching a maximum of 4.0
log2 at 2 weeks post challenge.
3.3.2. Viremia
All animals in group E showed viremia after
challenge, and a peak mean virus titer of 3.3
log10 TCID50/mL was observed at day 5
(Fig. 4). Viral clearance was observed for one
animal at 2 weeks, and for another at 3 weeks
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after challenge. The other animals in this group
stayed viremic till the end of the experiment
(3 weeks post challenge). In group F, one ani-
mal did not show any viremia at all. The mean
peak viremia in group F was reduced to 2.4
log10 TCID50/mL at 5 days post challenge
and to 1.0 log10 TCID50/mL at day 7, compared
to group E, and at the latter time point, this
reduction was signiﬁcant. For animals that
showed viremia, virus was cleared from the
blood for each one animal at day 5, 7 or 10,
and at day 14 for the two others. In group G,
the peak viremia at day 5 was not reduced,
but virus titers at day 7 were signiﬁcantly
reduced to 1.1 log10 TCID50/mL. Virus could
no longer be detected from 7 days post chal-
lenge for half of the animals. The other animals
in this group were virus-negative at 2 weeks
post challenge, but two of them again showed
a positive virus titer at 3 weeks.
3.4. Vaccination with BEI-inactivated virus
in Alhydrogel or Suvaxyn o/w adjuvant
3.4.1. Virus-speciﬁc and -neutralizing antibodies
One animal in the mock-vaccinated group
(group H) seroconverted at 7 days post
Figure 2. Serum-virus titers after challenge for group A (Mock-vaccinated control), B (Progressis), C (UV-
inactivated virus) and D (BEI-inactivated virus). Virus titers in serum (log10 TCID50/mL) were determined
by virus titration on PAM, followed by immunoperoxidase staining for the PRRSV nucleocapsid protein.
= challenge. Symbols represent individual animals and lines represent mean virus titers in each group.
The dashed line gives the mean titers for group A. The dotted line gives the detection limit for virus titration.
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Figure 3. PRRSV-speciﬁc IPMA antibody titers (log2) (upper panel) and VN antibody titers (log2) (lower
panel) after vaccination and challenge for group E (Mock-vaccinated control), F (IFA adjuvant) and G
(Alhdyrogel adjuvant) = primo vaccination, = booster vaccination and = challenge. Symbols
represent individual animals and lines represent mean IPMA or SN titers for each group. The dashed line
gives the mean titers for group E. The dotted line gives the detection limit for the IPMA or SN test.
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challenge, and the others at 10 days (Fig. 5,
upper panel). Five animals that were vaccinated
with BEI-inactivated virus in combination with
Alhydrogel adjuvant (group I) showed virus-
speciﬁc antibodies from 3 weeks after the ﬁrst
vaccination, and one animal from 1 week after
booster vaccination. Antibody titers in group I
were signiﬁcantly higher than in group H at 1
week post challenge. In the group that was vac-
cinated with BEI-inactivated virus in combina-
tion with Suvaxyn o/w adjuvant (group J),
three animals seroconverted at 3 weeks after
the ﬁrst vaccination, and the others at 1 week
after booster vaccination. Antibody titers in
group J were signiﬁcantly higher than in group
H at 1 and 2 weeks after booster vaccination,
and at 1 week post challenge. Antibody titers
in both vaccinated groups reached similar val-
ues after challenge.
VN antibodies could not be detected in
group H earlier than 3 weeks after challenge,
and it lasted more than 4 weeks before all
animals in this group had shown VN antibodies
(Fig. 5, lower panel). In group I, no animals
showed VN antibodies before challenge, but
all animals seroconverted for VN antibodies
between one and 2 weeks post challenge,
and at 2 weeks post challenge, titers were
Figure 4. Serum-virus titers after challenge for group E (Mock-vaccinated control), F (IFA adjuvant) and G
(Alhydrogel adjuvant). Virus titers in serum (log10 TCID50/mL) were determined by virus titration on PAM,
followed by immunoperoxidase staining for the PRRSV nucleocapsid protein. = challenge. Symbols
represent individual animals and lines represent mean virus titers in each group. The dashed line gives the
mean titers for group E. The dotted line gives the detection limit for virus titration.
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Figure 5. PRRSV-speciﬁc IPMA antibody titers (log2) (upper panel) and VN antibody titers (log2) (lower
panel) after vaccination and challenge for group H (Mock-vaccinated control), I (Alhydrogel adjuvant) and J
(Suvaxyn o/w adjuvant) = primo vaccination, = booster vaccination and = challenge. Symbols
represent individual animals and lines represent mean IPMA or SN titers for each group. The dashed line
gives the mean titers for group H. The dotted line gives the detection limit for the IPMA or SN test.
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signiﬁcantly different compared to group H (2.0
log2). In group J, however, all animals showed
signiﬁcantly high titers of VN antibodies already
at 1 (3.4 log2) and2 (3.1 log2)weeks after booster
vaccination. Starting from 3 weeks after booster
vaccination, VN antibody titers declined,
but they increased again after challenge to a
maximum value of 5.5 log2 and stabilized to
3.1 log2 at the end of the experiment.
3.4.2. Viremia
All animals in this experiment showed vire-
mia after challenge (Fig. 6). The mean peak
virus titer in group H was observed at day 5
and reached 2.6 log10 TCID50/mL. Virus was
cleared from the blood at 10 days post chal-
lenge for one animal, at 2 or 3 weeks for each
two animals and at 4 weeks for the sixth animal.
No signiﬁcant reduction in virus titers could be
observed in group I, but viral clearance was
already observed at day 7 (one animal), 10
(two animals) or 14 (three animals) after chal-
lenge. In group J, the peak virus titer was not
reduced, but four animals already showed viral
clearance at 1 week post challenge, and a ﬁfth
one at 2 weeks. The remaining animal was
virus-negative at 10 days post challenge, but
then again showed a high virus titer at 2 weeks,
followed by clearance of viremia at 3 weeks
post challenge.
4. DISCUSSION
Attenuated as well as inactivated vaccines
are currently used for the control of PRRSV
in the ﬁeld. Taking into account both safety
and ﬂexibility towards emerging virus strains,
inactivated vaccines are preferred over attenu-
ated vaccines, but in spite of these beneﬁts,
the efﬁcacy of current inactivated PRRSV vac-
cines is questionable [24, 35]. In the current
study, experimental inactivated PRRSV vac-
cines were developed, based on formerly opti-
mized inactivation procedures, and the
efﬁcacy of these vaccines was evaluated. As a
reference, the efﬁcacy of a commercial inacti-
vated PRRSV vaccine was simultaneously
tested in the ﬁrst experiment. This vaccine did
not induce virus-speciﬁc antibodies, and only
slightly elevated the antibody response after
challenge. These results are similar to a study,
performed by Zuckermann et al. [35], showing
that vaccination with this commercial vaccine
only resulted in an anamnestic humoral immune
response after challenge. Virus-speciﬁc anti-
body titers as measured by IPMA or ELISA
do not correlate with VN antibody titers and
hence do not provide any information about
protective immunity against PRRSV [33]. In
the present experiment, the VN antibody
response after infection in mock-vaccinated ani-
mals was delayed and weak, compared to the
virus-speciﬁc antibody response. This was not
surprising, as it has been described that the
VN antibody response against PRRSV is
strongly impaired [7, 12, 34]. Vaccination with
the commercial inactivated PRRSV vaccine did
not inﬂuence the VN antibody response after
challenge. This is in contrast with the study
from Zuckermann et al. [35] that showed an
anamnestic VN antibody response in pigs that
were vaccinated with this vaccine, and a study
from Scortti et al. [24] where vaccination with
another inactivated PRRSV vaccine slightly
improved the VN antibody response after chal-
lenge. This discrepancy may be due to the use
of other tests with different sensitivity for the
detection of VN antibodies [12, 32, 33, 35].
Delrue et al. [6] previously showed that inacti-
vation of PRRSV with UV radiation or BEI
does not inﬂuence the capacity of the inacti-
vated virus to get internalized in PAM, the
in vivo host cell type for the virus. As VN anti-
bodies block internalization of PRRSV in PAM,
the degree of internalization might be a measure
for conservation of neutralizing antigens after
inactivation [5]. In the current study, vaccina-
tion with both UV- or BEI-inactivated virus
with IFA as adjuvant strongly induced virus-
speciﬁc antibodies in all animals, and resulted
in an earlier and strongly elevated VN antibody
response after infection. The strong priming of
the VN antibody response by vaccination with
UV- or BEI-inactivated virus suggests that
intact neutralizing antigens were present
on the vaccine virus. Although the VN antibody
response was primed by vaccination with
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UV- or BEI-inactivated virus, no VN antibodies
could be induced by vaccination on itself in the
ﬁrst two experiments, except for one pig
that was vaccinated with BEI-inactivated virus
in combination with IFA. The low immunoge-
nicity of neutralizing epitopes is characteristic
for the virus in itself, as the VN antibody
response after PRRSV infection is strongly
impaired [7, 12, 34]. To determine to what
extent the antibody response, induced by the
inactivated virus, was subject to the choice of
adjuvant, two different adjuvants that are suit-
able for ﬁeld use were tested in combination
with the BEI-inactivated virus. Vaccination in
combination with Alhydrogel, a commonly
used adjuvant in human and veterinary medi-
cine, also consistently induced virus-speciﬁc
antibodies, and primed the VN antibody
response. Nonetheless, both virus-speciﬁc and
neutralizing antibodies appeared later after vac-
cination or challenge and titers were lower if
Alhydrogel was used instead of IFA. The use
of a commercial o/w adjuvant for the BEI-inac-
tivated virus resulted in a comparable IPMA
antibody response as with Alhydrogel. Surpris-
ingly, vaccination in combination with the o/w
adjuvant not only primed the VN antibody
response, but also induced high titers of VN
antibodies before challenge. In addition, VN
antibodies after challenge rose to titers that were
Figure 6. Serum-virus titers after challenge for group H (Mock-vaccinated control), I (Alhydrogel
adjuvant) and J (Suvaxyn o/w adjuvant). Virus titers in serum (log10 TCID50/mL) were determined by virus
titration on PAM, followed by immunoperoxidase staining for the PRRSV nucleocapsid protein.
= challenge. Symbols represent individual animals and lines represent mean virus titers in each group.
The dashed line gives the mean titers for group H. The dotted line gives the detection limit for virus titration.
Vet. Res. (2009) 40:63 M. Vanhee et al.
Page 12 of 15 (page number not for citation purpose)
higher than those observed by vaccination with
IFA or Alhydrogel as adjuvant. The fact that
VN antibodies could be induced by vaccination
on itself directly proves that neutralizing epi-
topes are conserved on the BEI-inactivated vir-
ion, but the immunogenicity of these epitopes
seems subject to the choice of adjuvant. In gen-
eral, this is the ﬁrst report of an inactivated
PRRSV vaccine that manages to induce a
strong VN antibody response by vaccination
on itself.
VN antibodies can completely block
PRRSV infection of PAM in vitro [5], but the
role of these antibodies for in vivo protection
against PRRSV is a matter of debate (reviewed
in [13]). It has been shown that viremia after
infection can be cleared in the absence of
detectable levels of VN antibodies in serum
and otherwise viremia can sometimes persist
despite the presence of VN antibodies [8, 29].
On the other hand, Labarque et al. showed that
clearance of virus from lungs and serum coin-
cides with the appearance of VN antibodies in
serum and broncho-alveolar lavage ﬂuid [10].
Moreover, experiments where passive transfer
of VN antibodies was performed before infec-
tion with PRRSV showed that these antibodies
are able to fully protect pigs against viremia and
reproductive failure [14, 20]. These data indi-
cate that although other mechanisms may be
involved in protection against PRRSV, the pres-
ence of sufﬁcient amounts of VN antibodies
contributes to clearance of viremia, can protect
against reproductive failure and even can be
sufﬁcient to prevent infection. In the present
study, virus was cleared from the blood in
mock-vaccinated animals between 2 and 4
weeks post infection when almost no VN anti-
bodies were present, indicating that viral clear-
ance in those animals took place independent of
VN antibodies. Animals that were vaccinated
with the commercial inactivated PRRSV vac-
cine also did not consistently develop VN anti-
bodies post infection, although a slight
reduction in viremia was observed compared
to control animals. Piras et al. recently showed
that this vaccine can induce a virus-speciﬁc
interferon-c (IFN-c) response that may contrib-
ute to viral clearance [21]. Another study how-
ever showed that a majority of the IFN-c
response induced by this vaccine is not
PRRSV-speciﬁc and is probably induced by a
non-viral component of the vaccine [35]. All
experimental vaccines tested in the current
study were able to reduce viremia, starting from
1 week post infection. A signiﬁcant reduction in
virus titers could be observed in animals that
were vaccinated with UV- or BEI-inactivated
virus, the latter in combination with both IFA
and Alhydrogel, at 7 or 10 days post infection.
Moreover, viral clearance was systematically
observed at earlier time points in vaccinated
animals, compared to control animals, and
reduction and/or clearance of viremia always
coincided with the appearance of VN antibod-
ies. The use of different adjuvants affected the
efﬁcacy of the experimental vaccine regarding
reduction of viremia, analogous to the induction
of VN antibodies. However, in spite of the
strong induction of VN antibodies by BEI-inac-
tivated virus in combination with the o/w adju-
vant, viremia was still present during the ﬁrst 5
days after infection in all animals. Remarkably,
VN antibodies were hardly present during this
time period, but once they appeared again, virus
was cleared in all but one animal. Probably,
higher titers of VN antibodies are needed at
the time of challenge to offer full protection
against the high dose of virus used to infect
the animals. In this study, an experimental inac-
tivated PRRSV vaccine was developed by the
use of a formerly optimized inactivation proce-
dure and a suitable adjuvant. This vaccine was
able to induce VN antibodies, and reduced the
duration of viremia after infection to 1 week.
This is the ﬁrst report of an inactivated PRRSV
vaccine that manages to induce VN antibodies,
which offers new perspectives for the
development of effective and safe PRRSV
vaccines.
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